Long-term symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol

被引：0
|
作者：
Kane, JM
Swyzen, W
Wu, XL
McQuade, R
Esteinou, RG
Van Tran, Q
Marcus, R
Crandall, D
机构：
[1] Zucker Hillside Hosp, Glen Oaks, NY USA
[2] Bristol Myers Squibb Co, US Med Affairs, Plainsboro, NJ USA
[3] Bristol Myers Squibb Co, Biostat & Data Management, Wallingford, CT 06492 USA
[4] Otsuka Pharmaceut Co Ltd, Global Med Affairs, Princeton, NJ USA
[5] Bristol Myers Squibb Co, Global Med Affairs, Lawrenceville, NJ USA
[6] Otsuka Pharmaceut Co Ltd, US Med Affairs, Rockville, MD USA
[7] Bristol Myers Squibb Co, Pharmaceut Res Inst, Global Clin Res, Wallingford, CT 06492 USA
[8] Bristol Myers Squibb Co, Neurosci, Plainsboro, NJ USA
来源：
BIOLOGICAL PSYCHIATRY | 2006年 / 59卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
394
引用
收藏
页码：121S / 121S
页数：1
相关论文
共 50 条
  • [21] Efficacy of aripiprazole (amdoal) in the long-term treatment of schizophrenia
    Tsukarzi, E. E.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (03) : 94 - 97
  • [22] Long-term effects of aripiprazole on affective symptoms of schizophrenia
    Inmaculada, O
    Stock, E
    Archibald, D
    Tourkodimitris, S
    Kujawa, M
    Marcus, R
    Carson, W
    Iwamoto, T
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S417 - S417
  • [23] Long-term effects of aripiprazole on affective symptoms of schizophrenia
    Octavio, I
    Stock, E
    Archibald, D
    Tourkodimitris, S
    Kujawa, M
    Marcus, R
    Carson, W
    Iwamoto, T
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S261 - S261
  • [24] Efficacy and safety of aripiprazole and haloperidol in patients with schizophrenia
    Sulejmanpasic-Arslanagic, G.
    Kapetanovic, D.
    Srebrenka, B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S490 - S491
  • [25] Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
    Kasper, S
    Lerman, MN
    McQuade, RD
    Saha, A
    Carson, WH
    Ali, M
    Archibald, D
    Ingenito, G
    Marcus, R
    Pigott, T
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2003, 6 (04): : 325 - 337
  • [26] LONG-TERM HEALTH OUTCOMES IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH THE LONG-ACTING INJECTABLE ANTIPSYCHOTIC ARIPIPRAZOLE LAUROXIL FOR 1 YEAR
    Gasper, S. M.
    Dingman, S.
    Wang, M.
    Roy, B. D.
    VALUE IN HEALTH, 2022, 25 (07) : S314 - S315
  • [27] LONG-TERM MAINTENANCE THERAPY WITH DEPOT HALOPERIDOL IN SCHIZOPHRENIA
    ZBYTOVSKY, J
    HOMEOSTASIS IN HEALTH AND DISEASE, 1991, 33 (5-6): : 287 - 287
  • [28] The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia
    Jeong, CY
    Conley, RR
    Kelly, DL
    Shim, JC
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (06) : 613 - 615
  • [29] Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate
    Peuskens, Joseph
    Trivedi, Jitendra K.
    Brecher, Martin
    Svensson, Ola
    Miller, Frank
    Meulien, Didier
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 289S - 289S
  • [30] CLINICAL REMISSION IN SCHIZOPHRENIA PATIENTS TREATED WIHT ARIPIPRAZOLE FOR UP TO ONE YEAR
    Campos Mangas, Ma Carmen
    Ruiz Feliu, Miguel Angel
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 261 - 262
12345